Sarah Tabrizi
British neurologist and neuroscientist
Follow Sarah Tabrizi on Notably News to receive short updates to your email — rarely!
| 2024 | Elected Fellow of the Royal Society, a prestigious scientific honor highlighting her outstanding scientific achievements. |
| 2024 | Elected to US National Academy of Medicine, recognizing her significant contributions to medical research. |
| 2023 | Received the Arvid Carlsson Award from Lund University, acknowledging her notable work in neuroscience. |
| 2022 | Awarded the MRC Millennium Medal in recognition of her significant medical research contributions. |
| 2022 | Honored with the Osler Medal and Lecture from the Association of Physicians of Great Britain and Ireland. |
| 2022 | Received the Huntington's Disease Society of America Outstanding Research Award for her groundbreaking work in Huntington's disease research. |
| 2022 | Developed the Huntington's Disease Integrated Staging System (HD-ISS) alongside colleagues, creating a novel four-stage framework for assessing disease progression from birth, similar to cancer staging systems. |
| 2020 | Published the Huntington's Disease Young Adult Study (HD-YAS), which studied premanifest HD gene carriers approximately 24 years from predicted onset of clinical symptoms, providing critical information on the earliest signs of neurodegeneration. |
| 2020 | Reviewed the potential of antisense oligonucleotides to treat neurodegenerative diseases in Science journal. |
| 2019 | Awarded the Yahr Award from the World Congress of Neurology for her contributions to neuroscience. |
| 2019 | Received the Alexander Morison Medal from the Royal College of Physicians of Edinburgh. |
| May 2019 | Published full results of the Huntingtin-lowering antisense oligonucleotide trial in The New England Journal of Medicine. |
| 2018 | Received the Cotzias Award from the Spanish Society of Neurology. |
| 2018 | Honored with the NHS70 Women Leader award. |
| 2017 | Awarded the Seventh Leslie Gehry Brenner Prize for Innovation in Science by the Hereditary Disease Foundation. |
| 2017 | Identified an important new genetic modifier of Huntington's disease progression (MSH3, a mismatch repair protein), which opened up new research avenues into targeting DNA repair pathways as potential therapeutics. |
| December 2017 | Announced 'top line' results from the Phase 1b/2a safety trial of the first clinical trial of a 'gene silencing' or huntingtin-lowering antisense oligonucleotide (ASO) drug in Huntington's disease patients, receiving widespread national and international media coverage. |
| 2016 | Gave a keynote presentation at the Google Zeitgeist Minds conference about her research and the prospect of gene silencing for neurodegenerative disease. |
| 2014 | Elected Fellow of the Academy of Medical Sciences. |
| 2013 | Began serving as a member of the Wellcome Trust Expert Review Group on Cellular and Molecular Neuroscience. |
This contents of the box above is based on material from the Wikipedia article Sarah Tabrizi, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.